Spyre Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $90,494 |
Gross Profit | 45,247 | |||
EBITDA | -96,121 | -36,200 | -75,641 | -62,530 |
EBIT | -105,719 | -81,639 | -75,641 | -57,172 |
Net Income | -96,121 | -36,200 | -69,005 | -62,530 |
Net Change In Cash | 0 | 0 | 0 | 90,494 |
Free Cash Flow | -77,495 | -69,877 | -57,372 | -44,578 |
Cash | 82,727 | 162,007 | 97,185 | 85,721 |
Basic Shares | 88,410 | 84,729 | 78,548 | 75,088 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $886 | $886 | $2,329 |
Gross Profit | -171,653 | 886 | -78 | 2,329 |
EBITDA | -209,562 | -207,967 | -242,303 | -81,987 |
EBIT | -219,562 | -128,564 | -243,047 | -83,951 |
Net Income | -155,203 | -208,018 | -338,790 | -83,815 |
Net Change In Cash | 0 | 886 | 886 | 2,329 |
Free Cash Flow | -169,252 | -157,410 | -99,910 | -80,182 |
Cash | 85,721 | 89,423 | 188,893 | 34,863 |
Basic Shares | 64,056 | 47,027 | 6,897 | 3,371 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.94 |
2026-06-30 | -$0.36 |
2026-03-31 | -$0.74 |
2025-12-31 | -$0.74 |